Medical Hypotheses
Volume 55, Issue 5 , Pages 415-418 , November 2000

Deficient detoxifying capacity in the pathophysiology of preeclampsia

  • E.M. Roes

      Affiliations

    • Department of Obstetrics and Gynaecology, University Hospital, Nijmegen, The Netherlands
    • ,
  • M.T.M. Raijmakers

      Affiliations

    • Laboratory of Gastroenterology, University Hospital, Nijmegen, The Netherlands
    • ,
  • P.L.M. Zusterzeel
    • ,
  • M.C.F.M. Knapen

      Affiliations

    • Department of Obstetrics and Gynaecology, University Hospital, Nijmegen, The Netherlands
    • ,
  • W.H.M. Peters

      Affiliations

    • Laboratory of Gastroenterology, University Hospital, Nijmegen, The Netherlands
    • ,
  • E.A.P. Steegers

      Affiliations

    • Department of Obstetrics and Gynaecology, University Hospital, Nijmegen, The Netherlands

Received 24 September 1999 ,Accepted 6 January 2000.

References 

    REFERENCES
  1. Steegers EAP, Post van der JAM. Hypertension in pregnancy. In:  Kurjak A editors. Textbook of Perinatal Medicine. New York: Parthenon Publishing; 1997;p. 1889–1911
  2. Weinstein L. Preeclampsia/eclampsia with hemolysis, elevated liver enzymes, and thrombocytopenia. Obstet Gynecol. 1985;66:657–660
  3. Piering WF, Garancis JG, Becker CG, Beres JA, Lemann J. Preeclampsia related to a functioning extrauterine placenta: report of a case and 25-year follow-up. Am J Kidney Dis. 1993;21:310–313
  4. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Precelampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989;161:1200–1204
  5. Wickens D, Wilkins MH, Lunec J, Ball G, Dormandy TL. Free radical oxidation (peroxidation) products in plasma in normal and abnormal pregnancy. Ann Clin Biochem. 1981;18:158–162
  6. Maseki M, Nishigaki I, Hagihara M, Tomoda Y, Yagi K. Lipid peroxide levels and lipids content of serum lipoprotein fractions of pregnant subjects with or without pre-eclampsia. Clin Chim Acta. 1981;115:155–161
  7. Wang YP, Walsh SW, Guo JD, Zhang JY. The imbalance between thromboxane and prostacyclin in preeclampsia is associated with an imbalance between lipid peroxides and vitamin E in maternal blood. Am J Obstet Gynecol. 1991;165:1695–1700
  8. Walsh SW, Wang Y. Secretion of lipid peroxides by the human placenta. Am J Obstet Gynecol. 1993;169:1462–1466
  9. Uotila JT, Tuimala RJ, Aarnio TM, Pyykko KA, Ahotupa MO. Findings on lipid peroxidation and antioxidant function in hypertensive complications of pregnancy. Br J Obstet Gynaecol. 1993;100:270–276
  10. Chen G, Wilson R, Cumming G, Walker JJ, Smith WE, McKillop JH. Intracellular and extracellular antioxidant buffering levels in erythrocytes from pregnancy-induced hypertension. J Hum Hypertens. 1994;8:37–42
  11. Knapen MF, Mulder TP, Van Rooij IA, Peters WH, Steegers EA. Low whole blood glutathione levels in pregnancies complicated by preeclampsia or the hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol. 1998;92:1012–1015
  12. Hennig B, Chow CK. Lipid peroxidation and endothelial cell injury: implications in atherosclerosis. Free Radic Biol Med. 1988;4:99–106
  13. Walsh SW. Maternal–placental interactions of oxidative stress and antioxidants in preeclampsia. Semin Reprod Endocrinol. 1998;16:93–104
  14. Raijmakers MTM, Zusterzeel PLM, Peters WHM, Steegers EAP. Plasma thiol status in preeclampsia. Obstet Gynecol. 1999;
  15. Sies H, Sies H. Oxidative stress: Introductory remarks. Oxidative Stress. New York: Academic Press; 1985; p. 1–8
  16. Ishihara M. Studies on lipoperoxide of normal pregnant women and of patients with toxemia of pregnancy. Clin Chim Acta. 1978;84:1–9
  17. Wisdom SJ, Wilson R, McKillop JH, Walker JJ. Antioxidant systems in normal pregnancy and in pregnancy-induced hypertension. Am J Obstet Gynecol. 1991;165:1701–1704
  18. Davidge ST, Hubel CA, Brayden RD, Capeless EC, McLaughlin MK. Sera antioxidant activity in uncomplicated and preeclamptic pregnancies. Obstet Gynecol. 1992;79:897–901
  19. Uotila J, Tuimala R, Pyykko K. Erythrocyte glutathione peroxidase activity in hypertensive complications of pregnancy. Gynecol Obstet Invest. 1990;29:259–262
  20. Mikhail MS, Anyaegbunam A, Garfinkel D, Palan PR, Basu J, Romney SL. Preeclampsia and antioxidant nutrients: decreased plasma levels of reduced ascorbic acid, alpha-tocopherol, and beta-carotene in women with preeclampsia. Am J Obstet Gynecol. 1994;171:150–157
  21. Hubel CA, Kozlov AV, Kagan VE. Decreased transferrin and increased transferrin saturation in sera of women with preeclampsia: implications for oxidative stress. Am J Obstet Gynecol. 1996;175:692–700
  22. Walsh SW. Lipid peroxidation in pregnancy. Hypertens Preg. 1994;13:1–32
  23. Kappus H. Lipid peroxidation: mechanism, analysis, enzymology and biological relevance. In:  Sies H editors. Oxidative Stress. New York: Academic Press; 1985;p. 273–310
  24. Lyall F, Greer IA, Boswell F, Macara LM, Walker JJ, Kingdom JC. The cell adhesion molecule, VCAM-1, is selectively elevated in serum in pre-eclampsia: does this indicate the mechanism of leucocyte activation?. Br J Obstet Gynaecol. 1994;101:485–487
  25. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet. 1993;341:1447–1451
  26. Roberts JM, Hubel CA. Is oxidative stress the link in the two-stage model of pre-eclampsia?. Lancet. 1999;354:788–789
  27. Gulmezoglu AM, Hofmeyr GJ, Oosthuisen MM. Antioxidants in the treatment of severe pre-eclampsia: an explanatory randomised controlled trial. Br J Obstet Gynaecol. 1997;104:689–696
  28. Blake L, Shaw RW, Stark JM. Antioxidants in the treatment of severe pre-eclampsia: an explanatory randomised controlled trial [letter; comment]. Br J Obstet Gynaecol. 1997;104:1217–1218
  29. Chappell LC, Seed PT, Briley AL. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet. 1999;354:810–816
  30. Stamler JS, Slivka A. Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev. 1996;54:1–30
  31. Bray TM, Taylor CG. Tissue glutathione, nutrition, and oxidative stress. Can J Physiol Pharmacol. 1993;71:746–751
  32. Rumack BH, Peterson RC, Koch GG, Amara IA. Acetaminophen overdose. 662 cases with evaluation of oral acetylcysteine treatment. Arch Intern Med. 1981;141:380–385
  33. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1988;319:1557–1562
  34. Wang PH, Yang MJ, Lee WL, Chao HT, Yang ML, Hung JH. Acetaminophen poisoning in late pregnancy. A case.report. J Reprod Med. 1997;42:367–371
  35. Johnston RE, Hawkins HC, Weikel JH. The toxicity of N-acetylcysteine in laboratory animals. Semin Oncol. 1983;10:17–24
  36. Horowitz RS, Dart RC, Jarvie DR, Bearer CF, Gupta U. Placental transfer of N-acetylcysteine following human maternal acetaminophen toxicity. J Toxicol Clin Toxicol. 1997;35:447–451
  37. Giorgieri S, D’Antuono A, Panak K, Ruiz O, Diaz L. Monitoring of homocysteine and related compounds in blood.by MEKC. J Capillary Electrophor. 1997;4:257–260
  38. Holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet. 1991;20:123–134
  39. Galley HF, Howdle PD, Walker BE, Webster NR. The effects of intravenous antioxidants in patients with septic shock. Free Radic Biol Med. 1997;23:768–774
  40. Bernard GR, Wheeler AP, Arons MM. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest. 1997;112:164–172
  41. Akerlund B, Jarstrand C, Lindeke B, Sonnerborg A, Akerblad AC, Rasool O. Effect of N-acetylcysteine (NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial. Eur J Clin Pharmacol. 1996;50:457–461
  42. Furst DE, Clements PJ, Harris R, Ross M, Levy J, Paulus HE. Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis. 1979;38:356–361
  43. Louwerse ES, Weverling GJ, Bossuyt PM, Meyjes FE, de Jong JM. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol. 1995;52:559–564

PII: S0306-9877(00)91079-X

doi: 10.1054/mehy.2000.1079

Medical Hypotheses
Volume 55, Issue 5 , Pages 415-418 , November 2000

Article Tools